[{"orgOrder":0,"company":"Verseau Therapeutics","sponsor":"3S Bio Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Anti-VSIG4 antibodies","moa":"VSIG4","graph1":"Oncology","graph2":"Preclinical","graph3":"Verseau Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verseau Therapeutics \/ 3SBio","highestDevelopmentStatusID":"4","companyTruncated":"Verseau Therapeutics \/ 3SBio"}]

Find Clinical Drug Pipeline Developments & Deals by Verseau Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the terms of the agreement, Sunshine Guojian received an exclusive license to develop and commercialize a select number of MCM antibodies for all human oncology indications in Greater China, including mainland China, Taiwan, Hong Kong and Macau.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          December 14, 2020

                          Lead Product(s) : Anti-VSIG4 antibodies

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : 3S Bio Inc

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank